Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company's pipeline, applying Dante's internal siRNA and mRNA technology to rare and common diseases.

Since the company's foundation, Dante has invested in a robust R&D program with the goal to create end–to–end solutions from diagnosis to therapy. Dante's program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante's pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co–development to achieve validation and partner externally on clinical trials and commercialization.

"Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development," said Andrea Riposati, CEO of Dante Genomics. "When we founded Dante Genomics, we felt we had a responsibility to deliver personalized medicine beyond diagnosis so that no patient would be facing a diagnosis with no effective treatments. It is this holistic approach that challenges and motivates us as a company to accelerate science to save more lives."

Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre–clinical phase. The newest addition to Dante's discovery program pipeline is an mRNA oncology therapeutic in the molecular discovery phase meant to strengthen the immune system against certain cancer types. In co–development with US biotechnology company Protelica, Dante has therapies in respiratory disease and ovarian cancer, both in the non–regulatory pre–clinical phase.

Dante's mRNA COVID vaccine program development began in early 2021 and has recently completed the regulatory pre–clinical phase and is ready for its first in–human.

"My academic background has taught me the value of RNA therapeutics, and Dante's internal R&D leverages mRNA and siRNA technology to accelerate time to patients from concept to clinic," said Mattia Capulli, Chief Scientific Officer of Dante Genomics. "The data and advanced timeline of our mRNA vaccine program demonstrates Dante's high quality RNA platform and the reproducibility of this model applied to other clinical therapies.

The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The company name, Dante Genomics, comes from the compound of humanity and science. "Dante" refers to the Italian humanitarian poet and "Genomics" refers to the powerful science that takes place in a genomics lab. Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions. The Company's holistic approach to medicine spans from sequencing and variant interpretation to discovery drug development.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.


Laura D'Angelo
VP of Investor Relations
+39 0862 191 0671

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e163117–b6e3–40cc–8ecc–48cd9d72e8ce

GLOBENEWSWIRE (Distribution ID 8560383)

Preql raises $7M to build the future of data transformation

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Preql, a no–code data transformation solution, announced that it has raised $7 million in seed funding, led by Bessemer Venture Partners with participation from Felicis, and top founders in the analytics ecosystem including Taylor Brown from Fivetran, Keenan Rice from Looker, Tristan Handy from Dbt Labs, Eldad Fakash from Firebolt, and Benn Stancil from Mode. Preql's platform allows business users to structure data for reporting without having to write SQL or rely on specialized data talent.

Preql builds upon the innovation of tools like Snowflake and Fivetran, which have made aspects of the analytics workflow accessible to organizations without data engineering resources. The next evolutionary step in the modern data stack is to allow business users to manage their own logic for reporting "" something that's not possible today without advanced SQL and data transformation expertise.

Preql's Co–Founders and Co–CEOs, Gabi Steele and Leah Weiss, met while leading data teams at WeWork and went on to found a successful data engineering and visualization consultancy. During their time at WeWork, they experienced a disconnect between business users who need data for decision making and the data teams who structure and prepare data for analysis. Business users have to pass along definitions to data modeling specialists, who maintain logic in code but lack sufficient business context. Even with exceptional data talent, the result of this handoff is often lack of trust in data, frustrated data teams, and costly data investments without a clear path to ROI.

Preql's funding comes at a moment where companies of all sizes are now investing in data cloud data storage and ingestion tools. The cloud storage market is growing 22.3% each year. Despite these investments in modern infrastructure, few companies have the internal resources required to shape their data for analysis. "There's a misconception that simply storing data will help your organization become data driven. Data storage is necessary, but the hard part is agreeing on what you want to measure, how you want to measure it, and then translating that business logic into code," said Leah Weiss, Co–Founder. "Preql gives business users the ability to contextualize their data and customize definitions, but then abstracts away the complex work of data transformation."

Preql's technology sits on top of the data warehouse, predicts the data model required for your business, and then lets business users customize metric definitions. It compiles all of that logic and delivers reporting ready datasets back in your warehouse, something that previously took months of manual effort from highly skilled data teams. "We've seen first hand the pain business users and data teams experience while building out a central source of truth for reporting," said Gabi Steele, Co–Founder. "We are deeply committed to delivering a design forward and intuitive solution that business users will love and understand, and that more mature data teams are grateful for because it saves them so much back and forth."

"We're excited to partner with Preql to make data capabilities more accessible to organizations and verticals that are currently underserved," said Amit Karp, Partner at Bessemer Venture Partners. "We were really impressed with the unique insight the founders bring to this problem and the clarity of their vision." Viviana Faga, General Partner at Felicis adds, "we couldn't be more thrilled to partner with Gabi and Leah, who are on a mission to change the way data is transformed and accessed, better serving the needs of business users at every company."

About Preql
Preql is building automated data transformation for business users. Its technology empowers business users to access analysis–ready data in minutes without having to learn SQL or rely on a data team. Preql is backed by Bessemer Venture Partners, Felicis, and several angel investors. Learn more at preql.com.

About Bessemer Venture Partners
Bessemer Venture Partners helps entrepreneurs lay strong foundations to build and forge long standing companies. With more than 135 IPOs and 200 portfolio companies in the enterprise, consumer and healthcare spaces, Bessemer supports founders and CEOs from their early days through every stage of growth. Bessemer's global portfolio includes Pinterest, Shopify, Twilio, Yelp, LinkedIn, PagerDuty, DocuSign, Wix, Fiverr and Toast and has $9 billion of capital under management. Bessemer has teams of investors and partners located in Tel Aviv, Silicon Valley, San Francisco, New York, London, Boston, Beijing and Bangalore. Born from innovations in steel more than a century ago, Bessemer's storied history has afforded its partners the opportunity to celebrate and scrutinize its best investment decisions (see Memos) and also learn from its mistakes (see Anti–Portfolio).

About Felicis
Founded in 2006, Felicis is a venture capital firm investing in companies reinventing core markets, as well as those creating frontier technologies. Felicis focuses on early stage investments and currently manages over $2.1B in capital across 8 funds. The firm is an early backer of more than 41 companies valued at $1B+. More than 91 of its portfolio companies have been acquired or gone public, including Adyen (IPO), Credit Karma (acq by Intuit), Cruise (acq by General Motors), Fitbit (IPO), Guardant Health (IPO), Meraki (acq by Cisco), Ring (acq by Amazon), and Shopify (IPO). The firm is based in Menlo Park, CA. Learn more at www.felicis.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/98753d0b–a231–4884–a213–3f20c212a9bf

GLOBENEWSWIRE (Distribution ID 8560456)